Sanofi (EPA:SAN) has been assigned a €89.50 ($104.07) price target by analysts at UBS Group in a research note issued on Tuesday, Borsen Zeitung reports. The firm presently has a “buy” rating on the stock. UBS Group’s price target suggests a potential upside of 9.33% from the stock’s previous close.
Other equities analysts also recently issued reports about the stock. Jefferies Financial Group set a €95.00 ($110.47) price target on shares of Sanofi and gave the company a “buy” rating in a report on Wednesday, November 27th. HSBC set a €79.00 ($91.86) price target on Sanofi and gave the company a “neutral” rating in a report on Wednesday, November 27th. Deutsche Bank set a €92.00 ($106.98) target price on shares of Sanofi and gave the stock a “buy” rating in a report on Friday, November 1st. JPMorgan Chase & Co. set a €81.00 ($94.19) price target on Sanofi and gave the company a “neutral” rating in a report on Friday, November 1st. Finally, Bank of America set a €100.00 ($116.28) price objective on shares of Sanofi and gave the stock a “buy” rating in a research report on Friday, September 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of €89.81 ($104.43).
SAN stock opened at €81.86 ($95.19) on Tuesday. Sanofi has a twelve month low of €63.09 ($73.36) and a twelve month high of €92.97 ($108.10). The firm’s fifty day simple moving average is €83.29 and its two-hundred day simple moving average is €78.94.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Featured Article: Put Option
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.